PTAB Statistics
Trial statistics
FY 2026 reports
Current fiscal year (FY) statistics to date:
Appeal Statistics
FY2026 reports
Current fiscal year (FY) statistics to date:
PTAB dashboards
More information regarding PTAB statistics is available using the PTAB dashboards.
Special Reports
Fiscal Year 2026
Fiscal Year 2026
Image
- Study of High-Volume Filers and Domestic University-Related Patentees in District Court Litigation at the PTAB (October 2025) – a report on the most active high-volume district court filer patentees (HVFs) and domestic university-related patentees (URPs) involved in district court litigation from January 1, 2019, through December 31, 2024, focusing on patentees whose utility and reissue patents were at issue in district court litigation in this timeframe.
Image
- PTAB Multiple Petitions Study Addendum (October 2025)– a simplified Inter Partes Review (IPR) analysis addendum for calculating overall IPR petition trends.
Image
- Orange Book/biologics study update through July 2025 (updated October 2025) – a report on AIA trials involving petitions challenging Orange Book-listed patents and biologic patents. Study methodology for identifying Orange book-listed and biologic patents is provided in the Fiscal Year 2021 Orange Book/biologics study posted below. Study methodology used to create the statistics are provided in this appendix.
Prior fiscal year reports
Fiscal Year 2024
Fiscal Year 2024
- Motion to Amend Study, Installment 9 through March 31, 2024 (updated June 2024) – a cumulative report on the outcomes of motions to amend in AIA trials, including data on pre-pilot motions to amend in AIA trials and for motions to amend under the Office’s pilot program
- Data for completed trials with a pre-pilot MTA through March 31, 2024 (June 2024) – a report on the data for the completed trials with a MTA
- Archives of Motion to Amend Studies – a compilation of reports concerning motions to amend since 2016
- Orange Book/biologics study update through March 2024 (updated June 2024) – a report on AIA trials involving petitions challenging Orange Book-listed patents and biologic patents. Study methodology for identifying Orange book-listed and biologic patents is provided in the Fiscal Year 2021 Orange Book/biologics study posted below. Study methodology used to create the statistics are provided in this presentation.
Fiscal Year 2023
Fiscal Year 2023
- Motion to Amend Study, Installment 8 through March 31, 2023 (updated August 2023) – a report on the outcomes of pre-pilot motions to amend in AIA trials and some limited data for motions to amend filed under the Office’s pilot program
- Data for completed trials with a pre-pilot MTA through March 31, 2023 (August 2023) – a report on the data for the completed trials with a pre-pilot MTA
- Archives of Motion to Amend Studies – a compilation of reports concerning motions to amend since 2016
- PTAB Multiple Petitions Study FY2021-2022 Update (July 2023) – a report on multiple petitions filed in AIA proceedings, including serial and parallel petitions
- PTAB Multiple Petitions Study Appendix (July 2023)
- PTAB Executive Summary of PTAB Multiple Petitions Study (July 2023)
- Orange Book/biologics study update through March 2023 (updated June 2023) – a report on AIA trials involving petitions challenging Orange Book-listed patents and biologic patents. Study methodology for identifying Orange book-listed and biologic patents is provided in the Fiscal Year 2021 Orange Book/biologics study posted below. Study methodology used to create the statistics are provided in this presentation.
Fiscal Year 2022
Fiscal Year 2022
- Motion to Amend Study, Installment 7 through March 31, 2022 (updated September 2022) – a report on the outcomes of pre-pilot motions to amend in AIA trials and some limited data for motions to amend filed under the Office’s pilot program
- Data for 155 completed trials with a pre-pilot MTA (September 2020) – a report on the data for the 155 completed trials with a pre-pilot MTA
- PTAB Parallel Litigation Study (June 2022) – a report on the impact of PTAB discretionary denials of AIA petitions when there is a parallel district court proceeding addressing the same patent.
- PTAB Parallel Litigation Study Appendix (June 2022)
- PTAB Executive Summary of Parallel Litigation Study (June 2022)
Fiscal Year 2021
Fiscal Year 2021
- Orange Book/biologics study update through June 2021 (updated August 2021) – a report on AIA trials involving petitions challenging Orange Book-listed patents and biologic patents. Study methodology for identifying Orange book-listed and biologic patents is provided in the Fiscal Year 2019 Orange Book/biologics study posted below. Study methodology used to create the statistics are provided in this presentation.
- Multiple Petitions Study (updated December 2020) – a report on multiple petitions filed in AIA proceedings, including serial and parallel petitions
Fiscal Year 2020
Fiscal Year 2020
- Motion to Amend Study, Installment 6 through March 31, 2020 (updated July 2020) – a report on the outcomes of pre-pilot motions to amend in AIA trials and some limited data for motions to amend filed under the Office’s pilot program
- Data for 504 completed trials with a pre-pilot MTA (July 2020) – a report on the data for the 504 completed trials with a pre-pilot MTA
- Trial statistics by patent and by claim (June 2020) – a report providing various AIA trial statistics, including results by petition, by patent, and by claim; also includes an update on multiple petitions.
Fiscal Year 2019
Fiscal Year 2019
- Orange Book/biologics study (July 2019) – a report on AIA trials involving petitions challenging Orange Book listed patents and biologic patents. The report also includes a study on district court pharmaceutical litigation. Below are the individual data files in .csv format for the Orange Book/biologics study and the data dictionaries, which provides names, definitions, and attributes for the data in the files, in .pdf:
- Parallel proceedings study (April 2019) – a report on interaction between parallel proceedings at the USPTO (e.g., AIA proceedings, reexam, and re-issue) involving issued patents
Fiscal Year 2018
Fiscal Year 2018
- Expanded panels study (March 2018) – a report on panel expansion in AIA trials
- Orange Book-listed patent study (March 2018) – a report on FDA-approved drug patents challenged in AIA trials
- Multiple petition study (October 2017) – a report on multiple petitions filed in AIA proceedings